VivoSeq
Respiratory

Atopic Asthma

20

Pipeline Programs↗

0

Active Trials↗

11

Companies Involved↗

Atopic Asthma is an emerging landscape with 20 programs across 11 companies. The most active players are Amgen, Pfizer, Altair Therapeutics, Inc.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

95/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 2A

Altair Therapeutics, Inc.

1 program

Phase 2P

Pulmagen Therapeutics

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

16 of 20 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody315%Protein / enzyme15%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 21 pipeline programs.

Analysis

Trial Status

22

clinical trials

Completed20 · 91%
Terminated1 · 5%
Unknown status1 · 5%

Clinical Trials

Trial Activity

22 trials

Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT02821416·46 enrolled
A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)
Completed·AAerovance, Inc.·Phase 2·NCT00535028·24 enrolled
Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma
Completed·SSolAeroMed Inc.·Phase 2·NCT02334553·12 enrolled
Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma
Completed·UUniversity of Saskatchewan·N/A·NCT02327234·13 enrolled
Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma
Completed·Amgen logoAmgen·Phase 1·NCT01405963·31 enrolled
A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma
Completed·Novartis logoNovartis·Phase 1·NCT03138811·28 enrolled
Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics
Completed·AAerovance, Inc.·Phase 2·NCT00535431·32 enrolled
Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects
Completed·IIcagen·Phase 2·NCT00861211·34 enrolled
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
Completed·Novartis logoNovartis·Phase 2·NCT01836471·345 enrolled
Evaluation of the Effect of Levalbuterol on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma
Completed·HHamilton Health Sciences Corporation·Phase 2·NCT00320034·15 enrolled
Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Completed·Pfizer logoPfizer·Phase 2·NCT00410280·30 enrolled
The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics
Completed·HHamilton Health Sciences Corporation·Phase 1·NCT00625989·12 enrolled
A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00394654·30 enrolled
Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Completed·AAltair Therapeutics, Inc.·Phase 2·NCT00941577·30 enrolled
The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics
Completed·NNorthwell Health·N/A·NCT01329939·26 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)